Advanced cardiovascular physiology in an individual with type 1 diabetes after 10-year ketogenic diet-Reference-Cited by-同舟云学术

Advanced cardiovascular physiology in an individual with type 1 diabetes after 10-year ketogenic diet

Published:2024-08-01 Issue:2 Volume:327 Page:C446-C461
ISSN:0363-6143
Container-title:American Journal of Physiology-Cell Physiology
language:en
Short-container-title:American Journal of Physiology-Cell Physiology

Author:

Watso Joseph C.¹^ORCID,Robinson Austin T.²^ORCID,Singar Saiful Anuar Bin³^ORCID,Cuba Jens N.¹,Koutnik Andrew P.⁴⁵^ORCID

Affiliation:

1. Cardiovascular and Applied Physiology Laboratory, Department of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, Florida, United States

2. Neurovascular Physiology Laboratory, Indiana University, Bloomington, Indiana, United States

3. Department of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, Florida, United States

4. Sansum Diabetes Research Institute, Santa Barbara, California, United States

5. Human Healthspan, Resilience, and Performance, Florida Institute for Human and Machine Cognition, Pensacola, Florida, United States

Abstract

Adults with type 1 diabetes (T1D) have a 10-fold higher risk for cardiovascular disease (CVD) compared with the general population. We assessed cardiovascular health metrics in an adult with T1D who presented with a euglycemic HbA1c after following a ketogenic diet for the past 10 years. Despite concerns about the ketogenic diet increasing CVD risk, the participant exhibited below-average CVD risk relative to others with T1D when considering all outcomes together.

Funder

U.S. Department of Defense

American Heart Association

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpcell.00694.2023

Reference192 articles.

1. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018

2. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022

3. The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence

4. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

5. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes